Clinical effects of viral relapse after interferon plus ribavirin in patients co-infected with human immunodeficiency virus and hepatitis C virus. [artículo]
Por: Pulido Ortega, Federico [Unidad VIH]
.
Colaborador(es): Servicio de Medicina Interna.
Editor: Journal of hepatology, 2013Descripción: 58(6):1104-12.Recursos en línea: Solicitar documento Resumen: Sustained viral response (SVR) after therapy with interferon-ribavirin (IF-RB) reduces liver-related (LR) complications and mortality in HIV/HCV-co-infected patients. Here, we assess the impact of end-of-treatment response with subsequent relapse (REL) on LR events (LR death, liver decompensation, hepatocellular carcinoma, or liver transplantation), and liver stiffness (LS) by transient elastography.
| Tipo de ítem | Ubicación actual | Signatura | Estado | Fecha de vencimiento |
|---|---|---|---|---|
Artículo
|
PC9167 (Navegar estantería) | Disponible |
Formato Vancouver:
Berenguer J, Álvarez-Pellicer J, Carrero A, Von Wichmann MA, López-Aldeguer J, Mallolas J et al. GESIDA HIV/HCV Cohort
Study Group. Clinical effects of viral relapse after interferon plus ribavirin in patients co-infected with human immunodeficiency virus and hepatitis C virus. J Hepatol. 2013 Jun;58(6):1104-12.
PMID: 23395690
Contiene 32 referencias
Sustained viral response (SVR) after therapy with interferon-ribavirin (IF-RB) reduces liver-related (LR) complications and mortality in HIV/HCV-co-infected patients. Here, we assess the impact of end-of-treatment response with subsequent relapse (REL) on LR events (LR death, liver decompensation, hepatocellular carcinoma, or liver transplantation), and liver stiffness (LS) by transient elastography.
No hay comentarios para este ejemplar.